Litcius/Paper detail

B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

Renaud Felten, Pierre‐Marie Duret, Élodie Bauer, N. Sedmak, Julien Djossou, Massiva Bensalem, M. Ardizzone, M. Geoffroy, A. Fan, Marion Couderc, Jean Hugues Salmon, Laurent Messer, Rose‐Marie Javier, Alain Meyer, Emmanuel Chatelus, Christelle Sordet, Luc Pijnenburg, Jérémy Fort, Marina Rinagel, J. Walther, Cassandre Fabre, Laurent Arnaud, Jean Sibilia, Nicolás Meyer, Francis Bérenbaum, Isabelle Chary-Valckenaere, Martin Soubrier, Jérémie Sellam, Jacques‐Eric Gottenberg

2021Annals of the Rheumatic Diseases20 citationsDOI

Topics & Concepts

MedicineDrugIn vivoMembranePharmacologyMembrane permeabilityCoronavirus disease 2019 (COVID-19)In vitroInternal medicineBiochemistryChemistryBiologyDiseaseInfectious disease (medical specialty)BiotechnologySARS-CoV-2 and COVID-19 ResearchLipid Membrane Structure and BehaviorMonoclonal and Polyclonal Antibodies Research
B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics | Litcius